US Stock MarketDetailed Quotes
ARWR Arrowhead Pharmaceuticals
- 28.750
- +0.450+1.59%
Close Jul 22 16:00 ET
3.57BMarket Cap-6796P/E (TTM)
28.900High27.830Low742.53KVolume28.470Open28.300Pre Close21.21MTurnover0.67%Turnover RatioLossP/E (Static)124.20MShares39.83052wk High7.38P/B3.18BFloat Cap20.67052wk Low--Dividend TTM110.69MShs Float162.500Historical High--Div YieldTTM3.78%Amplitude1.200Historical Low28.570Avg Price1Lot Size
Arrowhead Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | (Q3)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | -94.32%3.55M | -1.03%240.74M | -49.02%16.1M | -51.18%15.83M | -3.65%146.27M | 127.95%62.55M | 75.89%243.23M | -17.52%31.58M | -29.37%32.41M |
| Operating revenue | --0 | -94.32%3.55M | -1.03%240.74M | -49.02%16.1M | -51.18%15.83M | -3.65%146.27M | 127.95%62.55M | 75.89%243.23M | -17.52%31.58M | -29.37%32.41M |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 28.63%126.19M | 33.83%140.1M | 5.69%445.74M | 7.82%124.43M | 12.54%118.53M | -11.02%98.1M | 15.34%104.68M | 46.78%421.74M | 11.86%115.41M | 35.45%105.32M |
| Selling and administrative expenses | 8.01%24.64M | 12.69%23.19M | -25.96%90.93M | -23.58%24.17M | -28.62%23.37M | -32.62%22.82M | -16.31%20.58M | 51.66%122.82M | -17.40%31.62M | 83.33%32.74M |
| -General and administrative expense | 8.01%24.64M | 12.69%23.19M | -25.96%90.93M | -23.58%24.17M | -28.62%23.37M | -32.62%22.82M | -16.31%20.58M | 51.66%122.82M | -17.40%31.62M | 83.33%32.74M |
| Research and development costs | 35.04%101.12M | 39.19%116.49M | 18.80%353.19M | 19.76%99.86M | 31.28%94.76M | -1.45%74.88M | 27.26%83.7M | 44.08%297.31M | 26.78%83.38M | 21.67%72.18M |
| Depreciation amortization depletion | 4.94%425K | 2.23%412K | 0.19%1.62M | 0.25%405K | 0.25%404K | 0.25%405K | 0.00%403K | --1.61M | --404K | -30.16%403K |
| -Depreciation and amortization | 4.94%425K | 2.23%412K | 0.19%1.62M | 0.25%405K | 0.25%404K | 0.25%405K | 0.00%403K | --1.61M | --404K | -30.16%403K |
| Operating profit | -362.00%-126.19M | -224.07%-136.55M | -14.84%-205M | -29.23%-108.33M | -40.86%-102.7M | 15.91%48.17M | 33.46%-42.13M | -19.77%-178.51M | -29.20%-83.83M | -128.78%-72.91M |
| Net non-operating interest income expense | -100.00%-994K | -1,435.93%-2.57M | -160.14%-3.03M | -186.99%-1.38M | -179.52%-986K | -147.15%-497K | -114.45%-167K | -17.76%5.03M | 37.89%1.58M | -3.13%1.24M |
| Non-operating interest income | 37.06%6.25M | 4.47%2.8M | 203.97%15.3M | 145.42%3.89M | 236.45%4.17M | 332.64%4.56M | --2.68M | -17.76%5.03M | --1.58M | --1.24M |
| Non-operating interest expense | 43.25%7.24M | 88.38%5.37M | --18.33M | --5.26M | --5.16M | --5.06M | --2.85M | --0 | --0 | --0 |
| Other net income (expense) | 2,262.50%189K | -16.96%421K | 101.05%1.54M | 696.67%717K | 181.17%306K | -99.55%8K | 171.71%507K | -63.04%765K | -75.21%90K | -156.78%-377K |
| Other non- operating income (expenses) | 2,262.50%189K | -16.96%421K | 101.05%1.54M | 696.67%717K | 181.17%306K | -99.55%8K | 171.71%507K | -63.04%765K | -75.21%90K | -156.78%-377K |
| Income before tax | -366.37%-127M | -231.84%-138.69M | -19.56%-206.49M | -32.66%-108.99M | -43.50%-103.38M | 7.46%47.68M | 33.53%-41.79M | -22.62%-172.71M | -29.64%-82.16M | -140.76%-72.05M |
| Income tax | 0 | -19,588.24%-3.31M | -26.45%2.78M | -46.50%2.03M | 742K | 0 | 17K | 189,150.00%3.79M | 189,150.00%3.79M | 0 |
| Net income | -366.37%-127M | -223.78%-135.38M | -18.57%-209.28M | -29.17%-111.02M | -44.53%-104.13M | 7.46%47.68M | 33.50%-41.81M | -25.31%-176.49M | -35.61%-85.94M | -140.76%-72.05M |
| Net income continuous Operations | -366.37%-127M | -223.78%-135.38M | -18.57%-209.28M | -29.17%-111.02M | -44.53%-104.13M | 7.46%47.68M | 33.50%-41.81M | -25.31%-176.49M | -35.61%-85.94M | -140.76%-72.05M |
| Minority interest income | -69.77%-1.7M | -416.87%-2.51M | -828.07%-4M | -209.98%-1.34M | -1.18M | -999K | -486K | -431K | -431K | 0 |
| Net income attributable to the parent company | -357.42%-125.3M | -221.51%-132.86M | -16.59%-205.28M | -28.26%-109.68M | -42.89%-102.95M | 9.71%48.68M | 34.27%-41.33M | -25.00%-176.06M | -34.93%-85.51M | -140.76%-72.05M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -357.42%-125.3M | -221.51%-132.86M | -16.59%-205.28M | -28.26%-109.68M | -42.89%-102.95M | 9.71%48.68M | 34.27%-41.33M | -25.00%-176.06M | -34.93%-85.51M | -140.76%-72.05M |
| Basic earnings per share | -321.74%-1.02 | -217.95%-1.24 | -14.97%-1.92 | -25.93%-1.02 | -41.18%-0.96 | 9.52%0.46 | 35.00%-0.39 | -22.79%-1.67 | -32.79%-0.81 | -134.48%-0.68 |
| Diluted earnings per share | -326.67%-1.02 | -217.95%-1.24 | -14.97%-1.92 | -25.93%-1.02 | -41.18%-0.96 | 9.76%0.45 | 35.00%-0.39 | -22.79%-1.67 | -32.79%-0.81 | -134.48%-0.68 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg